US regulatory status: approved. Molecular target: Adrenergic receptor alpha.
- Target
- Adrenergic receptor alpha
- Mechanism
- Adrenergic receptor alpha antagonist
pharma · Alzheimer Disease · Amyotrophic Lateral Sclerosis · AMLX
Amylyx Pharmaceuticals EMEA
Amylyx Pharmaceuticals EMEA B.V.
Amylyx Pharmaceuticals EMEA drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
167 Employees
Public company Type
AMLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 167
- Programs
- 7
- Drugs
- 2
- Patents
- 9
Amylyx Pharmaceuticals EMEA pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Amylyx Pharmaceuticals EMEA drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Amylyx Pharmaceuticals EMEA in public FDA and regional records.